Evidence review: Efficacy and effectiveness of antidepressant treatment in primary care

General Hospital Psychiatry

Volumn 24, Issue 4, 2002, Pages 213-224

  Simon, Gregory E ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Antidepressant; Depression; Primary care; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CHRONIC DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DYSTHYMIA; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MENTAL PATIENT; PREDICTION; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; RECURRENT DISEASE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036297731     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-8343(02)00198-6     Document Type: Article

References (117)

1. The de facto US mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services
2. Anxiety and depression in a primary care clinic: Comparison of Diagnostic Interview Schedule, General Health Questionnaire, and practitioner assessments
3. Psychiatric illness in general practice: A detailed study using a new method of case identification
4. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients
5. Adequacy and duration of antidepressant treatment in primary care
6. A study of the use of antidepressant medication in general practice
7. Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialties
8. The quality of care for depressive and anxiety disorders in the United States
9. Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations
10. Treatment of depression - Newer pharmacotherapies
11. A comparison of drugs versus placebo for the treatment of dysthymia
12. Treatment of dysthymia and minor depression in primary care: A randomized trial in older adults
13. Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial
14. The Hopkins Symptom Checklist: A measure of primary symptom dimensions
15. Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 study
16. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study
17. Randomized controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care
18. Randomized controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care
19. Treating major depression in primary care practice: Eight-month clinical outcomes
20. Medications versus cognitive behavior therapy for severely depressed outpatients: Mega-analysis of four randomized comparisons
21. The severity of major depression and choice of treatment in primary care practice
22. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
23. A comparison of nefazodone, the cognitive-behavioral analysis system of psychotherapy, and their combination for the treatment of chronic depression
24. A multifaceted intervention to improve treatment of depression in primary care
25. Telephone counseling as an adjunct to antidepressant treatment in the primary care system: A pilot study
26. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care
27. SSRIs versus other antidepressants for depressive disorder
28. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial
29. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs
30. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo
31. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
32. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
33. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
34. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another
35. Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression
36. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: A comparative trial of fluoxetine versus imipramine
37. Should anxiety and insomnia influence antidepressant selection: A randomized comparison of fluoxetine and imipramine
38. Does pretreatment anxiety predict response to either bupropion or sertraline
39. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression
40. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication
41. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression
42. Cardiovascular effects of fluoxetine in depressed patients with heart disease
43. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease
44. Psychotropic drugs in the management of chronic pain syndromes
45. A systematic review of antidepressants in neuropathic pain
46. The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature
47. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
48. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder
49. Antidepressant therapy for unexplained symptoms and symptom syndromes
50. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain
51. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial
52. Double-blind trial of fluoxetine: Chronic daily headaches and migraine
53. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
54. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy syndromes
55. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity
56. Citalopram in patients with fibromyalgia - A randomized, double-blind, placebo-controlled study
57. A randomized trial of fluoxetine versus amitriptyline in musculoskeletal pain
58. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin
59. Venlafaxine for the treatment of neuropathic pain
60. Venlafaxine HCL in the treatment of painful peripheral diabetic neuropathy
61. Lithium augmentation in treatment resistant depression: Meta-analysis of placebo-controlled trials
62. The use of thyroid supplements to augment antidepressant medication
63. A review of the use of augmentation therapy for the treatment of resistant depression: Implications for the clinician
64. New approaches to the treatment of refractory depression
65. St John's. Wort for depression (Cochrane Review)
66. A systematic review, and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review
67. Effectiveness of St. John's Wort in major depression: A randomized controlled trial
68. Comparisons of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression
69. Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study
70. Three-year outcomes for maintenance therapies in recurrent depression
71. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: A randomized controlled trial in patients older than 59 years
72. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial
73. Relapse and recurrence of depression in primary care: Rate and clinical predictors
74. A randomized trial of relapse prevention of depression in primary care
75. Recurrence after recovery from major depressive disorder during 15 years of longitudinal follow-up
76. Long-term prognosis of depression in primary care
77. Collaborative management to achieve treatment guidelines: Impact on depression in primary care
78. Stepped collaborative care for primary care patients with persistent symptoms of depression
79. Recognition, management, and outcomes of depression in primary care
80. Why are patients prescribed psychotropic drugs by general practitioners? Results of an international study
81. Non-detection of depression by primary care physicians reconsidered
82. Who is at risk of nondetection of mental health problems in primary care
83. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995
84. Care for depression in HMO patients aged 65 and older
85. DEPRES II (Depression Research in European Society II). A patient survey of the symptoms, disability, and current management of depression in the community. DEPRES Steering Committee
86. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment
87. Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the Medical Outcomes Study
88. Patterns of antidepressant use in community practice
89. Course of antidepressant treatment, drug type, and prescriber's specialty
90. Longitudinal patterns of antidepressant prescribing in primary care in the UK: Comparison with treatment guidelines
91. Outcomes of "inadequate" antidepressant treatment in primary care
92. Prescribing patterns of antidepressant medications for depression in an HMO
93. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
94. Are there detectable differences in quality of care or outcome of depression across primary care providers?
95. The HEDIS Antidepressant Measure
96. New Measure National Results
97. Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians
98. Randomized trial of a depression management program in high utilizers of medical care
99. Improving depression treatment in community primary care practice: A randomized trial of the quEST intervention
100. Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial
101. Improving the recognition and management of depression: Is there a role for physician education
102. A randomized controlled trial of CQI teams, and Academic Detailing: Can they alter compliance with guidelines?
103. Controlled trials of CQI and academic detailing to implement a clinical practice guideline for depression
104. Training primary care physicians to recognize, diagnose, and manage depression: Does it improve patient outcomes
105. Achieving guidelines for treatment of depression in primary care: Is physician education enough?
106. Does physician education on depression management improve treatment in primary care?
107. Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial
108. Improving treatment of late life depression in primary care: A randomized clinical trial
109. The electronic medical record: Its role in disseminating depression guidelines in primary care practice
110. The electronic medical record
111. A randomized trial of monitoring, feedback, and management of care by telephone to improve depression treatment in primary care
112. Effect of antidepressant drug counseling and information leaflets on adherence to drug treatment in primary care: Randomised controlled trial
113. Effectiveness of antidepressant pharmacotherapy: The impact of medication compliance and patient education
114. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression
115. The cost-effectiveness of practice-initiated quality improvement for depression: Results of a randomized, controlled trial